[{"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Initiates Phase II clinical Trial on AQCH, A Phytopharmaceutical Drug, As Potential Treatment for COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Sun Pharmaceutical Industries Limited"},{"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PGI Rohtak to Start Phase-2 Trial of Bharat Biotech's COVAXIN","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Serum Institute of India"},{"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Gets CDSCO Nod to Conduct Phase III Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Plans to Complete Phase 3 Trial of Sputnik V Covid Vaccine by March End","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Dr. Reddy\\'s Laboratories"},{"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper begins GPP-Baladol clinical trials in COVID-19 patients at BJ Medical College & Sasoon General Hospital Pune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PNB Vesper"},{"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Successfully Completes Phase II Clinical Trials with Pegylated Interferon Alpha2b in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Zydus Cadila"},{"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets DGCI Nod for Phase 3 Clinical Trials with Biological Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Zydus Cadila"},{"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper Completes Phase 2 of Clinical Trials of GPP-Baladol on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PNB Vesper"},{"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kochi Firm PNB Vesper Life Completes Phase 2 Clinical Trial of Covid Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PNB Vesper"},{"company":"Hetero Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Gets SEC Approval for Phase 3 Trials of Sputnik V","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Hetero Biopharma"},{"company":"LAXAI Life Sciences","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"LAXAI Life Sciences"},{"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covid-19 Patients with Colchicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"CSIR-Indian Institute of Chemical Technology"},{"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper gets DCGI Nod to Begin Phase III Trials For PNB 001\/GPP-Balacovin for Covid-19 treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PNB Vesper"},{"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Gets DCGI Nod to Conduct Phase III Trials for Two-Dose Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Zydus Cadila"}]
Details:
Dr Reddy's recently received permission from DCGI to conduct phase II and III trials of the Russian vaccine. If it receives an approval to continue, it will recruit 1,400 subjects for phase III.
Lead Product(s):
Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases
Product Name: Sputnik V
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 28, 2020
Details:
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine used against the novel coronavirus, for emergency use in adults and children.
Lead Product(s):
ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases
Product Name: ZyCoV-D
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 05, 2021
Details:
The phase 3 trial will be conducted on a large patient population in 12 hospitals all over India. GPP- Balacovin is a novel and safe d that possesses significant efficacy to save the hospitalized patients with oxygen support, from the deadly coronavirus.
Lead Product(s):
GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases
Product Name: PNB-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 24, 2021
Details:
CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.
Lead Product(s):
Colchicine,Niclosamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
LAXAI Life Sciences
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 12, 2021
Details:
The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.
Lead Product(s):
Niclosamide
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
CSIR-Indian Institute of Chemical Technology
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 06, 2021
Details:
The SEC has asked the company to study and monitor the Sputnik V's immunogenicity on days 21, 24, and 48 of the trial. The company was also asked by the panel to “study and assess neutralising antibodies and gamma interferon,” says the minute of the meeting.
Lead Product(s):
Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases
Product Name: Sputnik V
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 30, 2021
Details:
The company, which has its labs in England, had in early September 2020 received approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support.
Lead Product(s):
GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases
Product Name: PNB-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 22, 2021
Details:
The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020.
Lead Product(s):
GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases
Product Name: PNB-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 12, 2021
Details:
In a regulatory filing, Zydus Cadila has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
Lead Product(s):
Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases
Product Name: PegiHep
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 03, 2020
Details:
Pegylated Interferon alpha – 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients; the Company will now commence Phase III clinical trials.
Lead Product(s):
Pegylated Interferon alpha-2b
Therapeutic Area: Infections and Infectious Diseases
Product Name: PegiHep
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 12, 2020
Market Place
News Type
Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations. 
